Ticker League

Operating Cash Flow for Regeneron Pharmaceuticals (REGN)

As of · Reported

Metric

Latest period

$1.08B

YoY change

+12.6%

5Y CAGR

+13.7%

Peak year (2021)

$7.08B

Operating Cash Flow history chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025

Latest: $4.98B

Operating Cash Flow growth chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025

Latest: +12.6%

Operating Cash Flow history table for Regeneron Pharmaceuticals (REGN) from 1991 to 2025

  • 2025$4.98B+12.6%
  • 2024$4.42B-3.8%
  • 2023$4.59B-8.4%
  • 2022$5.01B-29.2%
  • 2021$7.08B+170.5%
  • 2020$2.62B+7.7%
  • 2019$2.43B+10.7%
  • 2018$2.20B+67.9%
  • 2017$1.31B-12.0%
  • 2016$1.49B+11.7%
  • 2015$1.33B+76.9%
  • 2014$752.43M+27.8%
  • 2013$588.60M-888.8%
  • 2012−$74.61M-47.3%
  • 2011−$141.68M-247.1%
  • 2010$96.34M-233.4%
  • 2009−$72.23M-18.9%
  • 2008−$89.09M-425.5%
  • 2007$27.37M+18.6%
  • 2006$23.07M-176.2%
  • 2005−$30.30M+79.2%
  • 2004−$16.91M+175.7%
  • 2003−$6.13M-94.5%
  • 2002−$110.52M+92.8%
  • 2001−$57.32M+105.4%
  • 2000−$27.91M+102.2%
  • 1999−$13.80M+35.3%
  • 1998−$10.20M+67.2%
  • 1997−$6.10M-70.0%
  • 1996−$20.30M+11.5%
  • 1995−$18.20M-11.2%
  • 1994−$20.50M-31.9%
  • 1993−$30.10M+75.0%
  • 1992−$17.20M+152.9%
  • 1991−$6.80M—

Operating Cash Flow values are taken from Regeneron Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Operating Cash Flow at Regeneron Pharmaceuticals (REGN)

Operating Cash Flow for Regeneron Pharmaceuticals (REGN): headline value $1.08B · YoY +12.6%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

Regeneron Pharmaceuticals (REGN) most recent annual operating cash flow stands at $4.98B (2025) – grew 12.6% year-over-year.

Over 2020–2025 (5 years), Regeneron Pharmaceuticals operating cash flow expanded at a +13.7% compound annual rate, with mixed annual results across the window.

Regeneron Pharmaceuticals operating cash flow declined from $7.08B in 2021 to $4.98B in 2025, a 29.7% drawdown.

The record annual operating cash flow stands at $7.08B, reached in 2021; the historical low of −$141.68M was recorded in 2011.

Regeneron Pharmaceuticals Operating Cash Flow by Year

Regeneron Pharmaceuticals Operating Cash Flow 2025: $4.98B

Regeneron Pharmaceuticals operating cash flow in 2025 was $4.98B, grew 12.6% from 2024.

Regeneron Pharmaceuticals Operating Cash Flow 2024: $4.42B

2024's operating cash flow for Regeneron Pharmaceuticals came in at $4.42B, edged down 3.8% below 2023.

Regeneron Pharmaceuticals Operating Cash Flow 2023: $4.59B

Regeneron Pharmaceuticals posted operating cash flow of $4.59B in 2023, declined 8.4% below 2022.

Regeneron Pharmaceuticals Operating Cash Flow 2022: $5.01B

In 2022, Regeneron Pharmaceuticals reported operating cash flow of $5.01B, declined 29.2% below 2021.

Regeneron Pharmaceuticals Operating Cash Flow 2021: $7.08B

Regeneron Pharmaceuticals operating cash flow in 2021 was $7.08B.

See more financial history for Regeneron Pharmaceuticals (REGN).

Sector peers by Operating Cash Flow

Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest operating cash flow

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation